血中エンドトキシン除去カラム(PMX)の有用性と意義の確立に向けた多角的アプローチ(<特集>敗血症とアフェレシス)
スポンサーリンク
概要
- 論文の詳細を見る
PMX is now used clinically for the treatment of severe sepsis and septic shock not only in Japan, but also outside Japan, mainly in Europe and some Asian countries. Evidence-based medicine is becoming more and more important around the world, and definitive evidence of the efficacy of PMX is needed. The studies such as the EUPHRATES trial in North America and ABDO-MIX in France are currently recruiting patients. These studies are expected to give a definitive answer about the effectiveness of PMX. The complete mechanism of action of PMX remains unclear, although multiple effects are now being studied. An FDA approved blood endotoxin measurement method (EAA) demonstrated reduction of blood endotoxin level following treatments with PMX. EAA has also been shown to be a useful biomarker for patient selection, identifying those most likely to benefit from PMX treatments. Other humoral mediator levels known to induce organ dysfunction were decreased after PMX treatment. Immunoactive or immunodepressed monocyte and/or neutrophils could be removed with PMX, which may give an immunomodulatory effect leading to the normalization of immune status. Multiple approaches are still needed to arrive at a complete explanation for the mechanism of action of PMX.
- 2012-05-31
著者
関連論文
- 11.ポリミキシンB固定化繊維充填カラム「トレミキシン」について(医療機器・器材のセールスポイント)
- S-2-3 エンドトキシン吸着療法による循環動態の改善 : 臨床効果と機序解明の試み
- グラム陽性菌敗血症に対するアフェレシス治療 : 治療標的としてのスーパー抗原(新しい体外循環治療を学ぶ)
- 繊維状吸着体を利用した敗血症治療用血液デバイス
- エンドトキシン吸着材料
- 3) PMX("トレミキシン")の新しい適応(日本アフェレシス学会第13回関東甲信越地方会抄録)
- エンドトキシン除去カラムの基本設計・前臨床・臨床効果
- 高分子を用いた病因物質の選択吸着分離
- 血中エンドトキシン除去カラム(PMX)の有用性と意義の確立に向けた多角的アプローチ(敗血症とアフェレシス)